Endocannabinoid and serotonin systems interact during nicotine withdrawal to produce depression-like symptoms in mice
In nicotine-withdrawn mice, the endocannabinoid transport inhibitor AM404 reduced depression-like behavior through serotonin 5-HT1A receptor interaction, suggesting cannabinoid-serotonin crosstalk as a smoking cessation target.
Quick Facts
What This Study Found
Researchers investigated how the endocannabinoid and serotonin systems interact during nicotine withdrawal in mice.
Nicotine-dependent mice showed decreased serotonin 5-HT1A receptor levels in the diencephalon. The CB1 receptor antagonist AM251 reduced physical withdrawal signs, while the endocannabinoid transport inhibitor AM404 reduced depression-like behavior (immobility in the forced swimming test) in a dose-dependent manner.
Critically, the antidepressant-like effects of AM404 were blocked by both the CB1 antagonist AM251 and the 5-HT1A receptor antagonist WAY 100635. This demonstrated that both the cannabinoid and serotonin systems were required for the antidepressant effect.
This cross-system interaction suggested that targeting the endocannabinoid system could address the mood component of nicotine withdrawal through serotonergic mechanisms.
Key Numbers
Nicotine: 2 mg/kg, 4 injections daily, 15 days. AM251 (0.5-2 mg/kg) reduced abstinence signs. AM404 (0.5-2 mg/kg) dose-dependently reduced immobility. Both AM251 and WAY 100635 blocked AM404's antidepressant effect.
How They Did This
Controlled animal study. Nicotine dependence induced by subcutaneous injection (2 mg/kg, 4x daily, 15 days) in mice. AM404, AM251, and WAY 100635 tested for effects on abstinence signs, forced swimming test, and locomotor activity. Diencephalic 5-HT1A expression measured.
Why This Research Matters
Mood disturbances during nicotine withdrawal are a major driver of relapse. Identifying a cannabinoid-serotonin interaction suggested new pharmacological targets for smoking cessation.
The Bigger Picture
This study connected three major neurotransmitter systems (endocannabinoid, serotonin, nicotinic) in the context of addiction, revealing potential combination therapy targets for smoking cessation.
What This Study Doesn't Tell Us
Mouse model of nicotine dependence using injection rather than inhalation. The forced swimming test is a limited model of depression. Clinical translation is uncertain.
Questions This Raises
- ?Could drugs targeting both endocannabinoid and serotonin systems be more effective for smoking cessation than current treatments?
- ?Do similar interactions occur in human nicotine withdrawal?
Trust & Context
- Key Stat:
- Antidepressant effect required both cannabinoid and serotonin system activation
- Evidence Grade:
- Well-controlled animal study demonstrating cross-system interaction with dual antagonist confirmation, but limited to mouse models.
- Study Age:
- Published in 2011. Research on neurotransmitter system interactions in addiction has continued.
- Original Title:
- Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal.
- Published In:
- Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 13(4), 239-47 (2011)
- Authors:
- Mannucci, Carmen(3), Navarra, Michele, Pieratti, Antonella, Russo, Giuseppina A, Caputi, Achille P, Calapai, Gioacchino
- Database ID:
- RTHC-00506
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How are the endocannabinoid and serotonin systems related in quitting smoking?
In mice, enhancing endocannabinoid signaling reduced depression during nicotine withdrawal, but this effect was blocked by a serotonin receptor antagonist, showing both systems must work together.
Could this lead to new smoking cessation drugs?
The finding suggests that drugs targeting the endocannabinoid system could address mood-related relapse during smoking cessation. However, this has not been tested in human clinical trials.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
- thc-and-ssris-cannabis-antidepressants
Cite This Study
https://rethinkthc.com/research/RTHC-00506APA
Mannucci, Carmen; Navarra, Michele; Pieratti, Antonella; Russo, Giuseppina A; Caputi, Achille P; Calapai, Gioacchino. (2011). Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal.. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 13(4), 239-47. https://doi.org/10.1093/ntr/ntq242
MLA
Mannucci, Carmen, et al. "Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal.." Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2011. https://doi.org/10.1093/ntr/ntq242
RethinkTHC
RethinkTHC Research Database. "Interactions between endocannabinoid and serotonergic system..." RTHC-00506. Retrieved from https://rethinkthc.com/research/mannucci-2011-interactions-between-endocannabinoid-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.